Nature Biomedical Engineering自然·生物医学工程
Nature Biomedical Engineering(英文缩写 NAT BIOMED ENG),ISSN 2157-846X,eISSN 2157-846X,中文译名:自然·生物医学工程 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-01 至 2026-08-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 29.234 | Q1 |
| 2022 | 28.100 | Q1 |
| 2023 | 26.800 | Q1 |
| 2024 | 26.600 | Q1 |
| 2025 | 26.300 | Q1 |
Nature Biomedical Engineering 最新收录文献
-
1. Unsaturated phospholipids form multicompartment liposomes that extend release of hydrophilic drugs.
PMID:日期:2026-09-23该文献暂无摘要。
-
2. Ultra-slow release of hydrophilic drugs via multilamellar-multivesicular liposomes formed by unsaturated phospholipids.
PMID:日期:2026-09-23Maintaining therapeutic drug concentrations at a target site while limiting systemic exposure is difficult for hydrophilic drugs, which rapidly diffuse from the injection site. Liposomes are widely used carriers, yet designs based on rigid, saturated phospholipids aim to reduce membrane permeability but often yield modest loading and substantial burst release. Here we compared liposomes composed of phospholipids of identical chain length but varying unsaturation, prepared under matched conditions. Contrary to the expectation that unsaturation accelerates release, liposomes based on 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) showed approximately 3-fold higher loading, 11-fold lower initial release and 4-fold lower release at 7 days than saturated analogues. These effects correlated with the emergence of multilamellar and multivesicular structures and extended across diverse hydrophilic drugs. In a rat sciatic nerve block model, tetrodotoxin-loaded liposomes produced 2-3 weeks of blockade without systemic toxicity, establishing a simple platform for sustained local delivery.
-
3. Biomimetic graphitic carbon nitride nanoparticles for multiscale photomodulation and therapeutic intervention.
PMID:日期:2026-09-22Most organic matter on Earth originates from the conversion of solar energy through photosynthesis in chloroplasts. Here, drawing inspiration from photosynthesis, we develop hollow-sphere graphitic carbon nitride nanoparticles (hg-CN NPs) that can modulate biological activity from subcellular processes to whole‑tissue function. The homogeneous hg-CN NPs show responsiveness to light via both photoelectrochemical and photothermal mechanisms and can be spontaneously internalized with excellent cytocompatibility. Using a focusing laser, the hg-CN NPs enable intracellular optical stimulation with subcellular resolution, inducing calcium-transient release in multiple cells and propagation in primary cardiomyocytes and cardiac fibroblasts. At the multicellular scale, optical pacing and synchronization of cardiomyocyte beating is readily achieved by light-emitting diodes. Further, we demonstrate that hg-CN nanoparticles can be safely delivered and elicit measurable cortical and behavioural light responses in a model of advanced retinal degeneration. The application of hg-CN NPs to porcine retinal tissue ex vivo confirms their modulation capability to directly activate retinal ganglion cell activity under light-emitting diode photostimulation. Taken together, hg-CN NPs represent a versatile tool to address complex biomedical challenges through subcellular, intercellular and tissue-level photo-modulation.
-
4. Microfluidics-mediated spatial control of mRNA lipid nanoparticles primes translation and enhances vaccine potency.
PMID:日期:2026-09-22Despite the success of mRNA lipid nanoparticle therapeutics, bottlenecks persist in limited cellular expression and uncontrolled encapsulation and release kinetics. Here we introduce a microfluidics-based method, MIMAC (microfluidic integrated mRNA amplification circuit), that restructures preformed lipid nanoparticles by inserting a metabolic enhancing RNA to an internal peripheral compartment while relocating the therapeutic RNA towards the core. Rapid shear-mediated reorganization generates a defined peripheral-to-core RNA arrangement that enables sequential cytosolic availability: early release of the metabolic RNA elevates ATP levels up to 4.2-fold and enhances following translation of the therapeutic RNA. The approach is compatible with multiple nucleic acid types-including linear, circular and self-amplifying RNA and plasmid DNA-and with varied lipid formulations. In mice, the structured lipid nanoparticles improve a human papillomavirus cancer vaccine, suppressing tumour growth by 89.2% and increasing survival. Applied to SARS-CoV-2 vaccines, our method boosts antibody titres by 62.3- to 174.8-fold while maintaining potency at one-tenth the dose. A benchtop device produces 200 doses per hour, supporting scalable use.
-
5. Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B.
PMID:日期:2026-09-21Approved chronic hepatitis B therapies rarely result in functional cure, as they fail to permanently silence all transcriptionally active hepatitis B virus (HBV) DNA. CRMA-1001 employs an optimized epigenetic silencer that represses viral transcription through targeted deposition of DNA methylation on episomal and integrated HBV DNAs. Here we showed that in HBV mouse models, a single dose of CRMA-1001 produced >3-log reductions in viral biomarkers, which correlated with de novo methylation of HBV DNA. Three doses resulted in up to 90% of animals with undetectable hepatitis B surface antigen and HBV DNA by 6 months post treatment. In non-human primates, CRMA-1001 induced transient liver transaminase elevations only at the highest dose tested. Expression and DNA methylation profiling revealed no detectable unintended targets in the human genome. These findings support the initiation of clinical development of CRMA-1001 as a finite treatment course with the potential for functional cure in individuals living with chronic hepatitis B.
-
6. Orthotopic liver xenotransplantation from gene-modified pig to decedent human.
PMID:日期:2026-09-16Xenotransplantation offers a critical solution to global organ shortages. Recent reports show that genetically engineered porcine livers can provide auxiliary metabolic support in human recipients and non-human primates. However, orthotopic pig-to-human liver xenotransplantation remained a challenge owing to the liver immunological and physiological complexity. Here we report the orthotopic pig-to-human liver xenotransplantation in a brain-deceased individual. Throughout the 11-day observation period, the xenograft maintains continuous albumin and bile production with normal composition, albeit at a relatively low level. Systemic haemodynamic stability is maintained, although suboptimal hepatic perfusion resulting from microthrombosis occurred, which likely contributed substantially to late-phase hepatic functional decline. Coagulation abnormalities manifest as progressive thrombocytopenia and reduced clotting factor activity. Histopathological analysis reveals scant T/B cell infiltration and immunoglobulin G deposition, yet demonstrates prominent innate immune activation and immunoglobulin M-mediated complement activation. While certain positive indicators emerge, critical challenges including endothelial damage, microthrombosis and coagulopathy remain. This study highlights the importance of genetic engineering and targeted immunosuppressive approaches to advance the clinical translation of xenogeneic liver transplantation.
-
7. Author Correction: Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours.
7. 作者更正：放疗触发的肿瘤中铂类化疗前药还原PMID:日期:2026-09-10该文献暂无摘要。
-
8. Defining attributes of effective binders for AI-assisted CAR design.
PMID:日期:2026-09-09该文献暂无摘要。
-
9. Sequence and structural determinants of efficacious de novo chimaeric antigen receptors.
PMID:日期:2026-09-09Advances in generative protein design using artificial intelligence (AI) have enabled the rapid development of binders against heterogeneous targets, including tumour-associated antigens. Despite extensive biochemical characterization, these novel protein binders have had limited evaluation in candidate therapeutics, including chimaeric antigen receptor (CAR) T cells. Here we synthesize generative protein design workflows to screen 1,758 newly designed protein binders targeting BCMA, CD19 and CD22 for efficacy in scalable protein-binding, T-cell activation and in vivo killing assays. We characterize three main challenges that hinder the utility of de novo protein binders as CARs, including tonic signalling, occluded epitope engagement and off-target activity. We develop computational and experimental heuristics to overcome these limitations, including screens of sequence variants of individual parental structures, that retain on-target CAR activation while mitigating liabilities. Together, our framework accelerates the development of AI-designed proteins for future preclinical therapeutic screening, helping enable a new generation of cellular therapies.